consolidated financial results fiscal year ended december ifrs february company name otsuka holdings co ltd stock exchange listing tokyo stock exchange code number url httpswwwotsukacomen representative tatsuo higuchi president representative director ceo contact yuji kogure director investor relations department telephone scheduled date annual general meeting shareholders march scheduled date dividend payment commencement march scheduled date securities report submission march supplementary materials financial results yes earnings announcement financial results yes institutional investors analysts press figures rounded nearest million unless otherwise stated consolidated financial results fiscal year ended december consolidated operating results indicates percentage change previous fiscal year profit attributable profit total comprehensive revenue business profit operating profit owners year income year company millions yen millions yen millions yen millions yen millions yen millions yen fy fy reference share profit investments accounted using equity method fy million fy million business profit indicator ordinary earnings power calculated follows revenue cost sales selling general administrative expenses research development expenses share profit investments accounted using equity method due application ias income taxes amended may results fiscal year ended december retrospectively restated dilution basic earnings per share fiscal year ended december return equity basic earnings diluted earnings ratio profit ratio operating attributable owners per share per share tax total assets profit revenue company yen yen fy fy consolidated financial position ratio equity equity attributable equity attributable attributable owners total assets total equity owners owners company company company per share total assets millions yen millions yen millions yen yen december december due application ias income taxes amended may figures december retrospectively restated consolidated cash flows net cash flows provided net cash flows used net cash flows used cash cash equivalents operating activities investing activities financing activities end year millions yen millions yen millions yen millions yen fy fy dividends ratio dividends annual dividends per share equity dividends attributable first second third total dividends payout ratio owners quarter quarter quarter yearend total consolidated company end end end consolidated yen yen yen yen yen millions yen fy fy fy forecast due application ias income taxes amended may dividends payout ratio consolidated ratio dividends equity attributable owners company consolidated fiscal year ended december retrospectively restated forecasts consolidated operating results year ending december january december indicates percentage change previous fiscal year profit attributable basic earnings revenue business profit operating profit profit year owners per share company millions yen millions yen millions yen millions yen millions yen yen q ytd fy others changes significant subsidiaries fiscal year changes specified subsidiaries resulting change scope consolidation none changes accounting policies changes accounting estimates changes accounting policies required ifrs yes changes accounting policies due reasons none changes accounting estimates none please refer consolidated financial statements major notes notes consolidated financial statements changes accounting policies details number shares issued outstanding common stock number shares issued outstanding end fiscal year including treasury shares december shares december shares number shares treasury shares end fiscal year december shares december shares average number shares outstanding fiscal year fiscal year ended december shares fiscal year ended december shares report scope audits external auditor note ensure appropriate use forecasts comments particular forecasts forwardlooking statements included report based information currently available certain assumptions otsuka holdings co ltd hereinafter referred company deems reasonable actual performance results may differ significantly due various factors please refer overview operating results financial position forecasts consolidated financial results fiscal year ending december details regard assumptions matters concerning financial forecastthe company plans hold earnings release briefing institutional investors analysts press february presentation materials webcast briefing available companys website promptly briefingattachment index overview operating results financial position operating results fiscal year ended december research development activities financial position fiscal year ended december cash flow fiscal year ended december forecasts consolidated financial results fiscal year ending december basic rationale selection accounting standards consolidated financial statements major notes consolidated statements financial position consolidated statements income consolidated statements comprehensive income consolidated statements changes equity consolidated statements cash flows notes consolidated financial statements note going concern assumptions changes accounting policies significant accounting estimates judgments operating segments impairment assets earnings per share business combinations subsequent events overview operating results financial position fiscal year ended december ias income taxes amended may applied comparative analysis previous fiscal year made using retrospectively restated figures application standard material impact consolidated financial statements details changes accounting policies stated notes consolidated financial statements changes accounting policies consolidated financial statements major notes operating results fiscal year ended december company affiliated companies hereinafter referred group adopted business profit indicator ordinary earnings power calculated follows revenue cost sales selling general administrative expenses research development expenses share profit investments accounted using equity method millions yen fy fy fiscal year ended fiscal year ended change change december december revenue business profit research development expenses business profit operating profit profit tax profit year profit attributable owners company research development expenses impairment losses based concept total health care group operating businesses maintain promote health diagnose treat disease anticipate social issues brought highly uncertain world amid changing social environment due impact geopolitical risks etc group incorporate new technologies needs arising changes environment harness opportunities presented growing awareness health order demonstrate groups true value total healthcare company continue pursue initiatives aimed realization sustainable growth revenue fiscal year ended december totaled million previous fiscal year operating segments recorded increased revenue main factors growth sales four global products long acting antipsychotic agent abilify maintena antipsychotic agent rexulti vreceptor antagonist jynarque anti cancer agent lonsurf addition growth royalties milestones outlicensed products drove results pharmaceutical business result revenue grew significantly exceeding decline revenue expiry exclusive sales period vreceptor antagonist samsca treatment fluid retention patients heart failure hepatic cirrhosis japan furthermore nutraceutical business well sales pocari sweat nature made continued grow amid increasing health awareness business profit research development expenses million main factors follows one hand gross profit increased due high sales four global products increased royalties milestones licensed products hand amid efforts accelerate investment new businesses sga expense ratio reduced appropriately controlling selling general administrative expenses efficient investment existing businesses research development expenses totaled million mainly due development expenses based collaboration license agreement executed sumitomo pharma co ltd joint development commercialization related antipsychotic agent novel mechanism action well due steady progress zipalertinibtas development treatment nonsmall cell lung cancer sibeprenlimabvis development treatment iga nephropathy also impact exchange rate fluctuations result greater anticipated sales growth appropriate controls imposed selling general administrative expenses business profit increased significantly million operating profit decreased million main factors impact recording total million impairment losses fiscal year ended december due impairment loss avp drug agitation associated dementia due alzheimers disease fourth quarter fiscal year addition impairment losses products pertaining daiya foods inc collaboration sumitomo pharma co ltd recorded third quarter fiscal year profit year million profit attributable owners company million results business segment follows millions yen consumer pharmaceuticals nutraceuticals others adjustments total products revenue business profit reference fy millions yen consumer pharmaceuticals nutraceuticals others adjustments total products revenue business profit pharmaceuticals revenue pharmaceutical business fiscal year ended december totaled million business profit million main products four global products group positions long acting antipsychotic agent abilify maintena antipsychotic agent rexultirxulti vreceptor antagonist samscajinarcjynarque anticancer agent lonsurf four global products sales products totaled million brand name antipsychotic agent outside europe brand name antipsychotic agent europe brand name autosomal dominant polycystic kidney disease adpkd treatment multiple regions outside japan brand name adpkd treatment us long acting antipsychotic agent abilify maintena us sales increased atop growth prescriptions mainly due promoting efficacy product bipolar disorder schizophrenia patients problems adhering drug regimens well facetoface detailing activities impact exchange rate fluctuations japan sales grew steadily due stronger information provision activities bipolar disorder addition schizophrenia result sales abilify maintena totaled million antipsychotic agent rexultirxulti us drug sold adjunctive therapy major depressive disorder treatment schizophrenia may treatment agitation associated dementia due alzheimers disease group actively engaged activities raise awareness agitation associated dementia due alzheimers disease also conducting dtc advertising prescriptions grew sales increased mainly due enhancement facetoface detailing activities well impact exchange rate fluctuations japan sales increased boosted new prescriptions due enhancement detailing activities schizophrenia result sales rexultirxulti totaled million direct consumer vreceptor antagonist samsca japan number prescriptions autosomal dominant polycystic kidney disease adpkd increased number patients received treatment exceeded cases hand sales significantly decreased due impact launch generics treatment fluid retention patients heart failure hepatic cirrhosis also us drug sold treatment hyponatremia sales significantly decreased due impact launch generics result sales samsca totaled million vreceptor antagonist jinarcjynarque us sales increased significantly result increase number prescriptions adpkd mainly due continued efforts raise awareness disease provision information clinical data well impact exchange rate fluctuations result sales jinarcjynarque totaled million anticancer agent lonsurf us sales increased significantly due approval august additional indication treatment combination bevacizumab colorectal cancer recommendation combination therapy nccn guidelines impact exchange rate fluctuations europe sales increased due increase number prescriptions impact exchange rate fluctuations addition combination therapy approved july japan sales continued solid due increased awareness combination therapy following publication research paper etc result sales lonsurf totaled million cancer treatment guidelines used widely around world nutraceuticals revenue nutraceutical business fiscal year ended december totaled million business profit million main products group positions pocari sweat nature made nutrition sant sas brand three major brands sales brands totaled million total sales three nurture brands daiya foods inc brand equelle body maint million three major brands sales volume pocari sweat electrolyte supplement drink decreased temporarily due impact price revision april japan however sales volume increased summer year highest temperatures record due promotion consumption accompanying rising interest measures heat disorder daily life increase brand contact points drinking experiences sports events hot spa facilities factors including continuing education hydration replenishment electrolytes overseas people recognizing importance hydration replenishment electrolytes activities raise awareness tailored culture situation region building brand image many years initiatives sales volume increasing result sales volume increased overall brand leading increase sales sales nature made supplements pharmavite llc increased due expanded market share us backed high trust brand quality also boosted marketing activities social media impact exchange rate fluctuations nutrition sant sas brand sells health food products mainly europe expanding food services ecommerce although sales decline due impact business reorganization japanese yenbased sales increased mainly due growth main products gerbl impact exchange rate fluctuations japan meteorological agency average temperatures summer june august throughout japan highest since recordkeeping began iri data market advantage calendar ytd food drug mass excluding amazon costco services providing meals public institutions schools etc three nurture brands plantbased foods daiya foods inc brand saw decrease sales mainly due increased competition dairy alternative cheese market north america however efforts made enhance product lineup utilizing original technology expand distribution sales equelle food supplement brand containing equol supports womens health beauty grew japan due increased recognition product wideranging spread information product including seminars womens health due steady increase number ecommerce subscriptions body maint protective beverage brand containing plantbased lacticacid bacteria b although sales declined december new communication campaign started proposes manage ones physical condition daily basis preparation important day efforts made develop core users raise recognition increase consumption product lactiplantibacillus pentosus onricb strain isolated tokyo university agriculture otsuka pharmaceutical confirmed efficacy consumer products revenue consumer product business fiscal year ended december totaled million business profit totaled million part due increase share profit associates mineral water products sales mainstay brand crystal geyser remained par previous fiscal year japan mainly appealing brand value communicating environmental initiatives use lightweight bottles caps bottles made recycled raw materials although sales volume decreased due impact price revision sales volume match carbonated vitamin drink increased due increase number users existing products strong sales match salty lemon soda launched march match vitamin mikan launched october others revenue fiscal year ended december totaled million business profit million sales specialty chemical business remained par previous fiscal year despite delayed recovery semiconductor market stagnation chinese market sales fine chemical business increased mainly due increase sales antibiotic intermediates transportation warehousing business despite acquisition new external customers steady growth handling volume strengthening total healthcare distribution platform coordination logistics data sales decreased marginally due decline unit freight rates international transportation please refer supplement documents fact book sales product information httpswwwotsukacomenirlibrarymaterialshtml research development activities research development expenses fiscal year ended december totaled million primary areas research development well status new product development segment follows pharmaceuticals group conducts research development primary focus areas psychiatry neurology oncology group also conducts research development focusing fields yet fully addressed cardiovascular renal system etc research development expenses pharmaceutical business fiscal year ended december million research development activities pharmaceutical business carried fiscal year ended december summarized development treatment category brand name generic name area status code indication psychiatry opc rexulti brexpiprazole japan major depressive granted approval rxulti disorder additional indication neurology december japan agitation associated application filed dementia due approval alzheimers disease additional indication october us agitation associated granted approval dementia due additional indication alzheimers disease may europe major depressive discontinued business disorder reason agitation associated discontinued business dementia due reason alzheimers disease aripiprazole long abilify aripiprazole china schizophrenia granted approval may acting injection maintena aripiprazole abilify us schizophrenia granted approval april month long asimtufii bipolar disorder acting injection avp deuterium us negative symptoms discontinued strategic modified schizophrenia reason dextromethorphan quinidine sep japan bipolar depression discontinued studies due significant delay us recruitment progress oncology astx inaqovi decitabine europe myelodysplastic application filed cedazuridine syndromes approval additional indication december china myelodysplastic phase iii trial syndromes initiated october europe acute myeloid granted approval leukemia september astx tolinapant us solid tumors discontinued strategic lymphoma reason astx tolinapant us tcell lymphoma phase trial initiated astx decitabine february cedazuridine us acute myeloid discontinued strategic leukemia reason ap iclusig ponatinib china chronic myeloid application filed leukemia acute march lymphoblastic leukemia tas jeselhy pimitespib japan prostate cancer phase ii trial initiated september development treatment category brand name generic name area status code indication oncology tas lytgobi futibatinib japan unresectable biliary granted approval june tract cancer harboring fgfr gene fusions progressed chemotherapy europe cholangiocarci granted approval july noma tas japan nonsmall cell lung phase iii trial us cancer initiated june europe tas us prostate cancer discontinued strategic reason europe tas zipalertinib japan nonsmall cell lung phase iii trial initiated us cancer december europe ab zimberelimab japan upper phase iii trial initiated ab domvanalimab gastrointestinal tract june cancer japan nonsmall cell lung phase trial initiated cancer june ab zimberelimab japan solid tumors phase trial initiated tas futibatinib january opfc zinc chloride japan cancerous skin phase ii trial initiated ulcers july opb japan solid tumors discontinued strategic reason cardio opc samtasu tolvaptan sodium china cardiac edema application filed vascular phosphate december renal voclosporin japan lupus nephritis application filed system november etc bempedoic acid japan hyper phase iii trial initiated cholesterolemia february opc japan cardiac edema phase ii trial initiated january opf japan highcalorie application filed categories parenteral nutrition chronic renal failure opa moizerto difamilast china atopic dermatitis phase iii trial initiated february opcel mikeluna carteolol china glaucoma ocular phase iii trial initiated latanoprost hypertension ops china irritable bowel phase ii trial initiated syndrome june vis tbd autoimmune disease phase trial initiated january description status us europe application filed indicates application approval submitted accepted relevant authorities countries regions indicates application approval submitted relevant authorities nutraceuticals nutraceutical business group draws knowledge pharmaceutical business conduct research development scientifically based original products order maintain promote health people october skin care brand innersignal released innersignal sc rich cream beauty cream developed focus stratification stratum corneum research development expenses nutraceutical business fiscal year ended december million outermost four skin layers cellular turnover takes place facial skin layer plays important role moisture retention protective barrier functions consumer products consumer product business group engaged research development original unique products field food beverage part everyones daily life group creating proposing innovative products based themes food health targeting businesses retort foods beverages plantbased foods aim solving various issues associated changing society involving health environment population aging society research development expenses consumer product business fiscal year ended december million others businesses group primarily engaged research development specialty chemical products fine chemicals group focusing organic inorganic synthesis technologies conducting research development new products centered technology well nextgeneration fields research development expenses businesses fiscal year ended december million financial position fiscal year ended december millions yen change december december current assets noncurrent assets total assets current liabilities noncurrent liabilities total liabilities total equity assets total assets december million increase million compared million december current assets increased million noncurrent assets increased million current assets current assets december million increase million compared million december mainly due increases cash cash equivalents million trade receivables million inventories million income taxes receivable million noncurrent assets noncurrent assets december million increase million compared million december mainly due increases property plant equipment million goodwill million investments accounted using equity method million financial assets million deferred tax assets million partially offset decrease intangible assets million intangible assets decreased mainly due recording totaling million impairment losses including related avp development treatment agitation associated dementia due alzheimers disease daiya foods inc collaboration sumitomo pharma co ltd various assets increased overall result depreciation yen addition impact exchange rate fluctuations also increase property plant equipment due capital investment increases goodwill trademarks distribution rights others due acquisition bonafide health llc bonafide health increase deferred tax assets due increases elimination unrealized gains inventories tax effect impairment losses intangible assets b liabilities total liabilities december million increase million compared million december current liabilities increased million noncurrent liabilities decreased million current liabilities current liabilities december million increase million compared million december mainly due increases trade payables million bonds borrowings million income taxes payable million current liabilities million increase bonds borrowings due reclassification currentportion bonds current liabilities noncurrent liabilities noncurrent liabilities december million decrease million compared million december mainly due decreases bonds borrowings million financial liabilities million c equity total equity december million increase million compared million december mainly due increase retained earnings million consisted profit attributable owners company million net dividend payments million increase components equity million result depreciation yen cash flow fiscal year ended december cash cash equivalents december million increase million compared balance december fiscal year ended december net cash flows provided operating activities million net cash flows used investing activities million result capital investments pharmaceutical business nutraceuticals business toward sustainable growth well acquisition bonafide health nutraceuticals business net cash flows used financing activities million result repayments borrowings lease liabilities million dividends paid thus cash cash equivalents increased million operating cash inflows exceeded total investing financing cash outflows following provides details around cash flow movements fiscal year ended december cash flows operating activities net cash flows provided operating activities million increase million compared previous fiscal year cash flows provided operating activities fiscal year ended december mainly consisted million profit tax adjusted million depreciation amortization expenses million impairment losses reversal impairment losses million increase trade receivables million income taxes paid cash inflows operating activities increased million previous fiscal year despite decrease profit tax due recording impairment losses related avp daiya foods inc collaboration sumitomo pharma co ltd million increase outflow income taxes paid due large growth royalties milestones four global products outlicensed products pharmaceutical business drove business performance contributed significantly increase cash flow operating activities cash flows investing activities net cash flows used investing activities million increase outflows million compared previous fiscal year cash flows used investing activities fiscal year ended december mainly consisted million payments acquisition property plant equipment million payments acquisition intangible assets million payments acquisition subsidiaries bonafide health company specializing creation sale products womens health increase million outflows primarily due million increase payments acquisition property plant equipment million increase payments acquisition subsidiaries cash flows financing activities net cash flows used financing activities million decrease outflows million compared previous fiscal year cash flows used financing activities fiscal year ended december mainly consisted million net increase shortterm borrowings million repayments longterm borrowings million repayments lease liabilities million dividends paid forecasts consolidated financial results fiscal year ending december financial forecast fiscal year ending december follows millions yen fy actual fy forecast change change revenue business profit research development expenses business profit operating profit profit tax profit year profit attributable owners company research development expenses note fy projected exchange rate yenusd yeneur pharmaceutical business revenue expected increase results strongly driven growth royalty income four global products abilify maintena rexultirxulti jinarcjynarque lonsurf outlicensed products nutraceutical business revenue expected increase due growth sales three major brands pocari sweat nature made nutrition sant sas brand three nurture brands daiya foods inc brand equelle body maint regarding selling general administrative expenses group engage growth investment involving large new businesses take challenges new frontiers meanwhile group also promote cost adjustments existing businesses regarding research development expenses group expects invest sibeprenlimabvis development treatment iga nephropathy avp development treatment agitation associated dementia due alzheimers disease tas development treatment nonsmall cell lung cancer among others view toward achieving sustainable growth business profit expected higher one fiscal year ended december sales four global products nutraceutical business expected increase cost adjustments existing businesses promoted despite promotion investment new businesses operating profit expected increase due recording substantial impairment losses year fiscal year ending december company projects consolidated revenue million current fiscal year business profit research development expenses million business profit million operating profit million profit tax million profit year million profit attributable owners company million basic rationale selection accounting standards group adopted international financial reporting standards ifrs enhance international comparability financial reporting consolidated financial statements major notes consolidated statements financial position millions yen december december assets current assets cash cash equivalents trade receivables inventories income taxes receivable financial assets current assets subtotal assets held sale total current assets noncurrent assets property plant equipment goodwill intangible assets investments accounted using equity method financial assets deferred tax assets noncurrent assets total noncurrent assets total assets millions yen december december liabilities equity liabilities current liabilities trade payables bonds borrowings lease liabilities financial liabilities income taxes payable provisions contract liabilities current liabilities total current liabilities noncurrent liabilities bonds borrowings lease liabilities financial liabilities net defined benefit liabilities provisions contract liabilities deferred tax liabilities noncurrent liabilities total noncurrent liabilities total liabilities equity equity attributable owners company share capital capital surplus treasury shares retained earnings components equity total equity attributable owners company noncontrolling interests total equity total liabilities equity consolidated statements income millions yen fy fy january january december december revenue cost sales gross profit selling general administrative expenses share profit investments accounted using equity method research development expenses impairment losses income expenses operating profit finance income finance expenses profit tax income tax expenses profit year attributable owners company noncontrolling interests profit period earnings per share basic earnings per share yen diluted earnings per share yen consolidated statements comprehensive income millions yen fy fy january january december december profit year comprehensive income items reclassified profit loss remeasurements defined benefit plans financial assets measured fair value comprehensive income share comprehensive income investments accounted using equity method subtotal items may reclassified profit loss exchange differences translation foreign operations cash flow hedges share comprehensive income investments accounted using equity method subtotal total comprehensive income total comprehensive income year attributable owners company noncontrolling interests total comprehensive income year consolidated statements changes equity fy january december millions yen equity attributable owners company components equity financial assets treasury retained measured fair share capital capital surplus remeasurements shares earnings value defined benefit plans comprehen sive income balance january cumulative effects changes accounting policies restated balance profit year comprehensive income comprehensive income year purchase treasury shares dividends sharebased payment transactions changes ownership interests subsidiaries result loss control transfer components equity retained earnings total transactions owners balance december equity attributable owners company components equity noncontrolling exchange total equity interests differences total cash flow translation total hedges foreign operations balance january cumulative effects changes accounting policies restated balance profit year comprehensive income comprehensive income year purchase treasury shares dividends sharebased payment transactions changes ownership interests subsidiaries result loss control transfer components equity retained earnings total transactions owners balance december fy january december millions yen equity attributable owners company components equity financial assets treasury retained measured fair share capital capital surplus remeasurements shares earnings value defined benefit plans comprehen sive income balance january profit year comprehensive income comprehensive income year purchase treasury shares dividends sharebased payment transactions changes ownership interests subsidiaries result loss control transfer components equity retained earnings total transactions owners balance december equity attributable owners company components equity noncontrolling exchange total equity interests differences total cash flow translation total hedges foreign operations balance january profit year comprehensive income comprehensive income year purchase treasury shares dividends sharebased payment transactions changes ownership interests subsidiaries result loss control transfer components equity retained earnings total transactions owners balance december consolidated statements cash flows millions yen fy fy january january december december cash flows operating activities profit tax depreciation amortization expenses impairment losses reversal impairment losses share profit investments accounted using equity method finance income finance expenses increase inventories increase trade receivables increase decrease trade payables others subtotal interest dividends received interest paid income taxes paid net cash flows provided operating activities cash flows investing activities proceeds sales property plant equipment payments acquisition property plant equipment payments acquisition intangible assets proceeds sales redemption investments payments acquisition investments proceeds sales subsidiaries payments acquisition subsidiaries increase decrease time deposits others net cash flows used investing activities cash flows financing activities purchase treasury shares change shortterm borrowings net proceeds longterm borrowings repayments longterm borrowings repayments lease liabilities dividends paid capital contribution noncontrolling interests payments acquisition interests subsidiaries noncontrolling interests others net cash flows used financing activities increase cash cash equivalents cash cash equivalents beginning year effect exchange rate changes cash cash equivalents cash cash equivalents end year notes consolidated financial statements note going concern assumptions applicable changes accounting policies group applied ias income taxes amended may fiscal year ended december ifrs description new standard interpretations amendments clarification accounting treatment deferred taxes related assets liabilities ias income taxes arising single transaction application standard clarifies accounting treatments initial recognition transaction give rise equal taxable deductible temporary differences time transaction results recognition taxable deductible temporary differences deferred tax liabilities assets respectively consolidated statements financial position result application standard previous fiscal years consolidated financial statements retrospectively restated effect application decreased deferred tax assets million increased deferred tax liabilities million decreased total equity million consisted decreases retained earnings million components equity million noncontrolling interests million consolidated statements financial position december addition effect increased income tax expenses million decreased profit year million consolidated statements income fiscal year ended december due cumulative effect application standard beginning balance retained earnings fiscal year ended december decreased million consolidated statements changes equity significant accounting estimates judgments preparing ifrscompliant consolidated financial statements management required make judgments estimates assumptions may affect application accounting policies reported amounts assets liabilities revenue expenses actual results may differ estimates estimates underlying assumptions reviewed ongoing basis effects review accounting estimates recognized accounting period review conducted future accounting periods items may significant effects amounts recognized consolidated financial statements follows impairment intangible assets fair value measurement financial instruments recoverability deferred tax assets measurement defined benefit obligations estimation statutory contractual rebates related public health system us operating segments overview reportable segments groups reportable segments constituent units group separate financial information available subject periodic reviews board directors order make decisions allocation business resources evaluate business performance respective segments company holding company directs groups strategic planning decisionmaking monitors group operations provides various common services group companies business activities conducted groups subsidiaries associates centering healthcare business group operates activities inside outside japan relating following four reportable segments pharmaceuticals nutraceuticals consumer products others businesses group defines reportable segments follows pharmaceuticals comprises manufacturing sales prescription drugs intravenous solutions nutraceuticals comprises manufacturing sales functional beverages overthecounter drugs nutritional supplements consumer products comprises manufacturing sales mineral water soft beverages food products others encompasses logistics warehousing manufacturing sales chemicals evaluation systems led displays spectroanalysis devices revenues performance reportable segment segment profit based operating profit intersegment revenue transfers reflect reasonable prices intersegment transfers based market value revenues performance groups reportable segments follows fy january december millions yen reportable segment adjustments consolidated pharma nutra consumer others total ceuticals ceuticals products revenue revenue external customers intersegment revenue transfers total segment profit items depreciation amortization expenses share profit loss investments accounted using equity method impairment losses capital expenditures fy january december millions yen reportable segment adjustments consolidated pharma nutra consumer others total ceuticals ceuticals products revenue revenue external customers intersegment revenue transfers total segment profit items depreciation amortization expenses share profit loss investments accounted using equity method impairment losses capital expenditures details adjustments follows segment profit following table shows segment profit adjustments millions yen fy fy january january december december intersegment eliminations unallocated expenses income total unallocated expenses incurred administrative departments headquarters company certain subsidiaries items depreciation amortization expenses impairment losses adjustments include depreciation amortization expenses impairment losses property plant equipment intangible assets assets associated headquarters functions company certain subsidiaries capital expenditures adjustments include capital expenditures relating assets associated headquarters research functions company certain subsidiaries capital expenditures purchases property plant equipment goodwill intangible assets impairment assets fy fiscal year ended december group recorded impairment losses million fiscal year ended december million related pharmaceutical business pharmaceutical business group received complete response letter crl us food drug administration fda vadadustat treatment anemia prior dialysis phase indicating application ready approval present form result impairment losses million recorded carrying amounts inprocess research development recognized intangible assets related assets reduced zero fy fiscal year ended december group recorded impairment losses million fiscal year ended december million related pharmaceutical business million related nutraceutical business pharmaceutical business main impairment losses million impairment loss avp development treatment agitation associated dementia due alzheimers disease million impairment loss related intangible assets recorded based collaboration license agreement executed sumitomo pharma co ltd joint development commercialization concerning avp group received results phase iii clinical studies studies targeting agitation associated dementia due alzheimers disease indicating studies meet primary endpoint due delay beyond initially anticipated approval application timeline diminished probability market approval group reevaluated intangible assets process research development result impairment losses million recorded carrying amount intangible assets reduced recoverable amount value use calculation value use discount rate based pretax weighted average cost capital used group received results clinical studies relate intangible assets recorded based collaboration license agreement executed sumitomo pharma co ltd joint development commercialization indicating diamond diamond clinical studies phase iii evaluating ulotaront acutely psychotic adults schizophrenia meet primary endpoint due confirmed delay beyond initially anticipated approval application timeline group reevaluated intangible assets inprocess research development result impairment losses million recorded carrying amount intangible assets reduced recoverable amount value use calculation value use discount rate based pretax weighted average cost capital used nutraceutical business profitability daiya foods inc develops manufactures sells plantbased foods north america declined result increased competition dairy alternative cheese market north america accordingly group reduced carrying amount assets related daiya foods inc recoverable amounts recorded impairment losses million million goodwill million trademarks distribution rights others million intangible assets recoverable amounts measured fair value less costs disposal fair value less costs disposal measured primarily taking account analysis income approach calculated discounting estimated amount future cash flows next years based business plan reflecting past experience external information approved management using discount rate calculated pretax weighted average cost capital beyond projected period business plan subsequent growth rate estimated hierarchy fair value level earnings per share basis calculating basic earnings per share fy fy january january december december profit attributable owners company millions yen amount attributable ordinary equity holders company millions yen profit used calculation basic earnings per share millions yen weighted average number ordinary shares thousands shares basic earnings per share yen basis calculating diluted earnings per share fy fy january january december december profit used calculation basic earnings per share millions yen adjustments profit year millions yen profit used calculation diluted earnings per share millions yen weighted average number ordinary shares thousands shares increase ordinary shares weighted average number diluted ordinary shares thousands shares diluted earnings per share yen dilution earnings per share fy business combinations significant business combinations acquisition bonafide health llc pharmavite llc pharmavite consolidated subsidiary company entered agreement acquire shares bonafide health llc bonafide health company specializing creation sale products womens health acquisition completed november outline business combination name acquired company business description name acquired company bonafide health llc business description manufacture sale supplements medical devices primarily aimed womens health ii main reasons business combination bonafide health founded mission contribute womens health providing innovative safe effective choices company engaged researching developing marketing new natureinspired health products women products bonafide health grounded science endorsed healthcare professionals company addresses complex health needs women evolve age offering longterm sustained support acquisition bonafide health pharmavite expand existing portfolio womens health field comprised uqora novel urinary tract health brand equelle supplement equol iii date obtaining control november iv method obtaining control acquired company percentage equity voting rights acquired pharmavite consolidated subsidiary company acquired shares voting rights bonafide health cash consideration fair value consideration paid assets acquired liabilities assumed date control obtained millions yen amount fair value consideration paid cash fair value assets acquired liabilities assumed current assets noncurrent assets current liabilities noncurrent liabilities fair value assets acquired liabilities assumed goodwill direct cost acquisition million included selling general administrative expenses consolidated statements income acquired trade receivables contractual cash flows expected collected goodwill consists mainly synergies existing businesses excess earning power expected arise acquisition amount goodwill expected deductible tax purposes major components noncurrent assets allocated intangible assets million trademarks distribution rights others million intangible assets impact groups financial results revenue profit loss included groups consolidated statement income arising bonafide health date acquisition control immaterial disclosure revenue profit loss assuming date business combination january socalled pro forma information omitted impact immaterial contingent consideration contingent considerations recorded result business combinations involving neurovance inc recor medical inc etc contingent considerations acquisition neurovance inc consist milestones paid based progress development centanafadine compound development treatment adhd obtained group acquired neurovance inc march ones paid based revenue launch centanafadine maximum potential amounts milestones usd million usd million respectively contingent consideration milestone based development progress ultrasound renal denervation device acquired business combination recor medical inc june settled december fair value contingent considerations estimated based probabilityweighted present value potential amount paid counterparty fair value changes contingent considerations attributable time value recognized finance expenses one attributable changes nontimevalue recognized either income expenses changes fair value contingent considerations follows millions yen amount balance december changes fair value foreign currency translation adjustment balance december changes fair value settlement amount period foreign currency translation adjustment balance december subsequent events applicable